Format

Send to

Choose Destination
See comment in PubMed Commons below
Drug Healthc Patient Saf. 2013;5:79-99. doi: 10.2147/DHPS.S28801. Epub 2013 Mar 28.

Clinical use of anti-TNF therapy and increased risk of infections.

Author information

1
OU Physicians Center for Inflammatory Bowel Disease, University of Oklahoma Health Sciences Center ; Department of Internal Medicine, University of Oklahoma Health Sciences Center.

Abstract

Biologics such as antitumor necrosis factor (anti-TNF) drugs have emerged as important agents in the treatment of many chronic inflammatory diseases, especially in cases refractory to conventional treatment modalities. However, opportunistic infections have become a major safety concern in patients on anti-TNF therapy, and physicians who utilize these agents must understand the increased risks of infection. A literature review of the published data on the risk of bacterial, viral, fungal, and parasitic infections associated with anti-TNF therapy was performed and the clinical presentation, diagnostic tests, management, and prevention of opportunistic infections in patients receiving anti-TNF therapy were reviewed. Awareness of the therapeutic potential and associated adverse events is necessary for maximizing therapeutic benefits while minimizing adverse effects from anti-TNF treatments. Patients should be adequately vaccinated when possible and closely monitored for early signs of infection. When serious infections occur, withdrawal of anti-TNF therapy may be necessary until the infection has been identified and properly treated.

KEYWORDS:

anti-TNF therapy; infections

PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Support Center